468 related articles for article (PubMed ID: 32592145)
1. Identification of a Potential Peptide Inhibitor of SARS-CoV-2 Targeting its Entry into the Host Cells.
Baig MS; Alagumuthu M; Rajpoot S; Saqib U
Drugs R D; 2020 Sep; 20(3):161-169. PubMed ID: 32592145
[TBL] [Abstract][Full Text] [Related]
2. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.
Souza PFN; Lopes FES; Amaral JL; Freitas CDT; Oliveira JTA
Int J Biol Macromol; 2020 Dec; 164():66-76. PubMed ID: 32693122
[TBL] [Abstract][Full Text] [Related]
3. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
Qiao B; Olvera de la Cruz M
ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067
[TBL] [Abstract][Full Text] [Related]
4. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts.
Zhai X; Sun J; Yan Z; Zhang J; Zhao J; Zhao Z; Gao Q; He WT; Veit M; Su S
J Virol; 2020 Jul; 94(15):. PubMed ID: 32404529
[TBL] [Abstract][Full Text] [Related]
6. Highly conserved binding region of ACE2 as a receptor for SARS-CoV-2 between humans and mammals.
Hayashi T; Abiko K; Mandai M; Yaegashi N; Konishi I
Vet Q; 2020 Dec; 40(1):243-249. PubMed ID: 32921279
[TBL] [Abstract][Full Text] [Related]
7. Coevolution, Dynamics and Allostery Conspire in Shaping Cooperative Binding and Signal Transmission of the SARS-CoV-2 Spike Protein with Human Angiotensin-Converting Enzyme 2.
Verkhivker G
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33158276
[TBL] [Abstract][Full Text] [Related]
8. Investigation of the genetic variation in ACE2 on the structural recognition by the novel coronavirus (SARS-CoV-2).
Guo X; Chen Z; Xia Y; Lin W; Li H
J Transl Med; 2020 Aug; 18(1):321. PubMed ID: 32831104
[TBL] [Abstract][Full Text] [Related]
9. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
[TBL] [Abstract][Full Text] [Related]
10. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
Zhu Y; Yu D; Yan H; Chong H; He Y
J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
[TBL] [Abstract][Full Text] [Related]
11. Computational Alanine Scanning and Structural Analysis of the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Complex.
Laurini E; Marson D; Aulic S; Fermeglia M; Pricl S
ACS Nano; 2020 Sep; 14(9):11821-11830. PubMed ID: 32833435
[TBL] [Abstract][Full Text] [Related]
12. Molecular docking study of potential phytochemicals and their effects on the complex of SARS-CoV2 spike protein and human ACE2.
Basu A; Sarkar A; Maulik U
Sci Rep; 2020 Oct; 10(1):17699. PubMed ID: 33077836
[TBL] [Abstract][Full Text] [Related]
13. Perspectives on development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Zhang C; Zhou C; Shi L; Liu G
Hum Vaccin Immunother; 2020 Oct; 16(10):2366-2369. PubMed ID: 32961082
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 host tropism: An in silico analysis of the main cellular factors.
Rangel HR; Ortega JT; Maksoud S; Pujol FH; Serrano ML
Virus Res; 2020 Nov; 289():198154. PubMed ID: 32918944
[TBL] [Abstract][Full Text] [Related]
15. Designing Multi-Epitope Vaccines to Combat Emerging Coronavirus Disease 2019 (COVID-19) by Employing Immuno-Informatics Approach.
Naz A; Shahid F; Butt TT; Awan FM; Ali A; Malik A
Front Immunol; 2020; 11():1663. PubMed ID: 32754160
[TBL] [Abstract][Full Text] [Related]
16. Nanobodies: Prospects of Expanding the Gamut of Neutralizing Antibodies Against the Novel Coronavirus, SARS-CoV-2.
Konwarh R
Front Immunol; 2020; 11():1531. PubMed ID: 32655584
[No Abstract] [Full Text] [Related]
17. COVID-19 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2.
Mittal A; Manjunath K; Ranjan RK; Kaushik S; Kumar S; Verma V
PLoS Pathog; 2020 Aug; 16(8):e1008762. PubMed ID: 32822426
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
Fantini J; Chahinian H; Yahi N
Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32405156
[TBL] [Abstract][Full Text] [Related]
19. Potential chimeric peptides to block the SARS-CoV-2 spike receptor-binding domain.
Barh D; Tiwari S; Silva Andrade B; Giovanetti M; Almeida Costa E; Kumavath R; Ghosh P; Góes-Neto A; Carlos Junior Alcantara L; Azevedo V
F1000Res; 2020; 9():576. PubMed ID: 32802318
[No Abstract] [Full Text] [Related]
20. SARS-CoV-2 strategically mimics proteolytic activation of human ENaC.
Anand P; Puranik A; Aravamudan M; Venkatakrishnan AJ; Soundararajan V
Elife; 2020 May; 9():. PubMed ID: 32452762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
